Therapy In Preclinical Studies Attacking Range Of Hard-To-Treat Cancers, Including Lung And Gastric Cancers

Prophase Labs

03/05/2023 14:19

May 3 (Reuters) - Prophase Labs Inc  PRPH.O :
    * PROPHASE LABS' LINEBACKER-1 CANCER THERAPEUTIC SHOWS
PROMISING
MECHANISMS OF ACTION AS BOTH A MONO-THERAPY AND CO-THERAPY IN
PRECLINICAL STUDIES ATTACKING A RANGE OF HARD-TO-TREAT CANCERS,
INCLUDING LUNG AND GASTRIC CANCERS

Source text for Eikon:  ID:nGNX48DyHh 
Further company coverage:  PRPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))